Big Data for Operator Support in Chemical Plants

February 13, 2018

Driven by the development of the Internet and IoT, the amount of data we are generating every day has exploded in the last few years. Therefore, big data analytics has become increasingly important for many companies trying to mine data to better understand their business and make better decisions. Industrial companies are no exception. Industrial automation has led to plants being increasingly IT-centric and data-intense. Today, a typical process plant like a paper mill, a hot-rolling mill or a petrochemical plant generates a large amount of data throughout its entire life-cycle: e.g. measurement values, alarm and event logs, shift book logs, laboratory results, piping and instrumentation diagrams (P&ID).

Spotlight

Vertex Pharmaceuticals

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases. Founded in 1989 in Cambridge, Massachusetts, our corporate headquarters is now located in Boston’s Innovation District, and our international headquarters is in London, United Kingdom. We currently employ 2,100 people in the United States, Europe, Canada and Australia with nearly two-thirds of our staff dedicated to research and development. Vertex is consistently recognized as one of the industry’s top places to work by Science magazine, The Boston Globe, Boston Business Journal and the San Diego Business Jou

OTHER WHITEPAPERS
news image

Mechanical Vapor Recompression key to steam energy upgrade within a polyolefin plant

whitePaper | September 14, 2022

Reducing energy costs and creating more sustainable local energy sources is a familiar challenge across many industries. Polyolefin process plants, for example, require a considerable amount of energy, often in the form of steam.

Read More
news image

THE INTELLIGENT ENTERPRISE FOR THE CHEMICAL INDUSTRY

whitePaper | April 7, 2022

Mastering future challenges and delivering new customer experiences through innovative products, services, and business models

Read More
news image

CHEMICAL INHIBITORS TO RAS ONCOPROTEINS

whitePaper | May 19, 2022

RAS (KRAS, HRAS, and NRAS) is the most frequently mutated gene family in human cancers that have been considered “undruggable” due to the elusive nature of RAS inhibitors.

Read More
news image

Green Chemistry and Contract Synthesis – a Contradiction?

whitePaper | June 17, 2021

The topic of green chemistry is now also a challenge for contract synthesis suppliers. This is because more and more manufacturers of shampoos, detergents, paints, packaging and other consumer products are becoming increasingly concerned about the ecological footprint of their products. The trend is being fueled by consumers, who are increasingly prepared to spend more money on products that are better for the environment. But the political environment is also exerting major pressure on companies.

Read More
news image

Commercial Customs Operations Advisory Committee Next Generation Facilitation Subcommittee 21st Century Customs Framework Task Force Report

whitePaper | January 10, 2023

CBP, and the Partner Government Agencies (PGAs) to share inputs and perspectives on the 21CCF draft legislative concepts.

Read More
news image

Chemical Industry Growth in a Circular Economy

whitePaper | November 20, 2019

While sustainability has long been on the chemical industry agenda, the value paradigm is shifting fast. By capturing a share of this rapidly expanding market for reusable, renewable and recyclable products, chemical companies can turn these changes to their advantage and drive growth while helping to shape a greener, cleaner, more sustainable future.

Read More

Spotlight

Vertex Pharmaceuticals

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases. Founded in 1989 in Cambridge, Massachusetts, our corporate headquarters is now located in Boston’s Innovation District, and our international headquarters is in London, United Kingdom. We currently employ 2,100 people in the United States, Europe, Canada and Australia with nearly two-thirds of our staff dedicated to research and development. Vertex is consistently recognized as one of the industry’s top places to work by Science magazine, The Boston Globe, Boston Business Journal and the San Diego Business Jou

Events